<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: with companies with sales", fill: "#ba55d3"},
{source: "2: with companies with sales", target: "2: United States ", fill: "#ba55d3"},
{source: "2: United States ", target: "2: development", fill: "#ba55d3"},
{source: "2: development", target: "2: both traditional", fill: "#ba55d3"},
{source: "2: both traditional", target: "2: innovative healthcare products", fill: "#ba55d3"},
{source: "2: with companies with sales", target: "6: fluctuate materially", fill: "#cfcfc4"},
{source: "6: fluctuate materially", target: "6: market price", fill: "#cfcfc4"},
{source: "6: market price", target: "6: dependent upon", fill: "#cfcfc4"},
{source: "6: dependent upon", target: "6: cold season", fill: "#cfcfc4"},
{source: "6: cold season", target: "6: retail generally increase as", fill: "#cfcfc4"},
{source: "6: retail generally increase as", target: "6: population suffering from colds", fill: "#cfcfc4"},
{source: "6: fluctuate materially", target: "12: investors expectations due", fill: "#ff43a4"},
{source: "12: investors expectations due", target: "12: market price", fill: "#ff43a4"},
{source: "12: market price", target: "12: common stock may decline", fill: "#ff43a4"},
{source: "12: investors expectations due", target: "13: may continue", fill: "#d6cadd"},
{source: "13: may continue", target: "13: incur significant costs", fill: "#d6cadd"},
{source: "13: incur significant costs", target: "13: from product liability", fill: "#d6cadd"},
{source: "13: from product liability", target: "13: securities litigation", fill: "#d6cadd"},
{source: "13: securities litigation", target: "13: significant liability should use", fill: "#d6cadd"},
{source: "13: significant liability should use", target: "13: consumption", fill: "#d6cadd"},
{source: "13: consumption", target: "13: injury illness", fill: "#d6cadd"},
{source: "13: may continue", target: "19: adverse decision", fill: "#da1d81"},
{source: "19: adverse decision", target: "19: such litigation could", fill: "#da1d81"},
{source: "19: such litigation could", target: "19: significant damages", fill: "#da1d81"},
{source: "19: significant damages", target: "19: adverse publicity", fill: "#da1d81"},
{source: "19: adverse publicity", target: "19: which could materially adversely affect", fill: "#da1d81"},
{source: "19: which could materially adversely affect", target: "19: operations", fill: "#da1d81"},
{source: "19: operations", target: "19: financial condition", fill: "#da1d81"},
{source: "19: adverse decision", target: "30: concerning", fill: "#000f89"},
{source: "30: concerning", target: "30: additional adverse publicity", fill: "#000f89"},
{source: "30: additional adverse publicity", target: "30: prospects could", fill: "#000f89"},
{source: "30: prospects could", target: "30: materially adversely affected", fill: "#000f89"},
{source: "30: concerning", target: "37: possibilities", fill: "#0d98ba"},
{source: "37: possibilities", target: "37: unanticipated", fill: "#0d98ba"},
{source: "37: unanticipated", target: "37: otherwise negative research", fill: "#0d98ba"},
{source: "37: otherwise negative research", target: "37: development", fill: "#0d98ba"},
{source: "37: development", target: "37: proposed products", fill: "#0d98ba"},
{source: "37: proposed products", target: "37: ineffective", fill: "#0d98ba"},
{source: "37: ineffective", target: "37: may otherwise fail", fill: "#0d98ba"},
{source: "37: may otherwise fail", target: "37: regulatory clearances", fill: "#0d98ba"},
{source: "37: regulatory clearances", target: "37: proposed products while effective", fill: "#0d98ba"},
{source: "37: proposed products while effective", target: "37: commercialize", fill: "#0d98ba"},
{source: "37: commercialize", target: "37: sufficient product inventories", fill: "#0d98ba"},
{source: "37: sufficient product inventories", target: "37: customer demand", fill: "#0d98ba"},
{source: "37: customer demand", target: "37: broad market acceptance", fill: "#0d98ba"},
{source: "37: broad market acceptance", target: "37: attain broad distribution", fill: "#0d98ba"},
{source: "37: attain broad distribution", target: "37: retail shelf space", fill: "#0d98ba"},
{source: "37: retail shelf space", target: "37: proprietary rights", fill: "#0d98ba"},
{source: "37: proprietary rights", target: "37: by third parties preclude us from", fill: "#0d98ba"},
{source: "37: by third parties preclude us from", target: "37: marketing existing", fill: "#0d98ba"},
{source: "37: possibilities", target: "80: directors", fill: "#9b111e"},
{source: "80: directors", target: "80: issue shares", fill: "#9b111e"},
{source: "80: issue shares", target: "80: preferred stock", fill: "#9b111e"},
{source: "80: preferred stock", target: "80: outstanding shares", fill: "#9b111e"},
{source: "80: outstanding shares", target: "80: common stock", fill: "#9b111e"},
{source: "80: common stock", target: "80: issued could adversely impact", fill: "#9b111e"},
{source: "80: issued could adversely impact", target: "80: certificate", fill: "#9b111e"},
{source: "80: certificate", target: "80: incorporation permits", fill: "#9b111e"},
{source: "80: incorporation permits", target: "80: sole discretion", fill: "#9b111e"},
{source: "80: sole discretion", target: "80: authorized but", fill: "#9b111e"},
{source: "80: authorized but", target: "80: unissued preferred stock", fill: "#9b111e"},
{source: "80: directors", target: "START_HERE", fill: "#9b111e"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_trend">Market trend</a></td>
      <td>A market trend is a perceived tendency of financial markets to move in a particular direction over time. These trends are classified as secular for long time frames, primary for medium time frames, and secondary for short time frames.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_Chopper_and_Market_32_Supermarkets">Price Chopper and Market 32 Supermarkets</a></td>
      <td>Golub Corporation is an American supermarket operator. Headquartered in Schenectady, New York, it owns the chains Market 32 and Price Chopper Supermarkets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing">Pricing</a></td>
      <td>Pricing is the process whereby a business sets the price at which it will sell its products and services, and may be part of the business's marketing plan. In setting prices, the business will take into account the price at which it could acquire the goods, the manufacturing cost, the marketplace, competition, market condition, brand, and quality of product.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-price_competition">Non-price competition</a></td>
      <td>Non-price competition is a marketing strategy "in which one firm tries to distinguish its product or service from competing products on the basis of attributes like design and workmanship". It often occurs in imperfectly competitive markets because it exists between two or more producers that sell goods and services at the same prices but compete to increase their respective market shares through non-price measures such as marketing schemes and greater quality.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_liability">Product liability</a></td>
      <td>Product liability is the area of law in which manufacturers, distributors, suppliers, retailers, and others who make products available to the public are held responsible for the injuries those products cause. Although the word "product" has broad connotations, product liability as an area of law is traditionally limited to products in the form of tangible personal property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Anthropogenic_hazard">Anthropogenic hazard</a></td>
      <td>Anthropogenic hazards are hazards caused by human action or inaction. They are contrasted with natural hazards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/An_Essay_Concerning_Human_Understanding">An Essay Concerning Human Understanding</a></td>
      <td>An Essay Concerning Human Understanding is a work by John Locke concerning the foundation of human knowledge and understanding. It first appeared in 1689 (although dated 1690) with the printed title An Essay Concerning Human Understanding.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/De_Cive">De Cive</a></td>
      <td>De Cive ("On the citizen") is one of Thomas Hobbes's major works. The book was published originally in Latin from Paris in 1642, followed by two further Latin editions in 1647 from Amsterdam.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Letter_Concerning_Toleration">A Letter Concerning Toleration</a></td>
      <td>A Letter Concerning Toleration by John Locke was originally published in 1689. Its initial publication was in Latin, and it was immediately translated into other languages.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Concerning_the_Jews">Concerning the Jews</a></td>
      <td>"Concerning the Jews" is an 1899 short essay by Mark Twain. Twain had lived in Austria during 1896, and opined that the Habsburg empire used Jews as scapegoats to maintain unity in their immensely diverse empire.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Question_Concerning_Technology">The Question Concerning Technology</a></td>
      <td>The Question Concerning Technology (German: Die Frage nach der Technik) is a work by Martin Heidegger, in which the author discusses the essence of technology. Heidegger originally published the text in 1954, in Vorträge und Aufsätze.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Structural_material">Structural material</a></td>
      <td>Structural engineering depends on the knowledge of materials and their properties, in order to understand how different materials resist and support loads.\nCommon structural materials are:\n\n\n== Iron ==\n\n\n=== Wrought iron ===\n\nWrought iron is the simplest form of iron, and is almost pure iron (typically less than 0.15% carbon).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gordon_v._Virtumundo,_Inc.">Gordon v. Virtumundo, Inc.</a></td>
      <td>Gordon v. Virtumundo, Inc., 575 F.3d 1040, is a 2009 court opinion in which the United States Court of Appeals for the Ninth Circuit addressed the standing requirements necessary for private plaintiffs to bring suit under the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, or CAN-SPAM Act of 2003, 15 U.S.C. ch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Copyright_law_of_France">Copyright law of France</a></td>
      <td>The droit d'auteur (or French copyright law) developed in the 18th century at the same time as copyright developed in the United Kingdom. Based on the "right of the author" (droit d'auteur) instead of on "copyright", its philosophy and terminology are different from those used in copyright law in common law jurisdictions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Programming_language">Programming language</a></td>
      <td>A programming language is any set of rules that converts strings, or graphical program elements in the case of visual programming languages, to various kinds of machine code output. Programming languages are one kind of computer language, and are used in computer programming to implement algorithms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Generic_trademark">Generic trademark</a></td>
      <td>A generic trademark, also known as a genericized trademark or proprietary eponym, is a trademark or brand name that, because of its popularity or significance, has become the generic term for, or synonymous with, a general class of products or services, usually against the intentions of the trademark's owner.\nA trademark is said to become genericized—or, informally, to have suffered genericide—when it begins as a distinctive product identifier but changes in meaning to become generic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trademark">Trademark</a></td>
      <td>A trademark (also written trade mark or trade-mark) is a type of intellectual property consisting of a recognizable sign, design, or expression that identifies products or services from a particular source and distinguishes them from others. The trademark owner can be an individual, business organization, or any legal entity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>MATRIXX INITIATIVES INC      ITEM 1A RISK FACTORS     We  may fail to compete effectively, particularly against, larger more     established  <font color="blue">pharmaceutical</font> and <font color="blue">health products companies</font>, or low cost     <font color="blue">generic drug <font color="blue">manufacturers</font></font>, causing our business and operating results to     suffer          The <font color="blue">consumer health products industry</font> is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>We compete     <font color="blue">with companies with sales</font> in the <font color="blue">United States </font>that are engaged in the     <font color="blue">development</font> of <font color="blue">both traditional</font> and <font color="blue">innovative healthcare products</font></td>
    </tr>
    <tr>
      <td>Many of     these companies have much greater financial and technical resources and     production and marketing <font color="blue">capabilities</font> than we do</td>
    </tr>
    <tr>
      <td>As well, many of these     companies have already achieved <font color="blue"><font color="blue">significant</font> product acceptance</font> and brand     <font color="blue">recognition with respect</font> to products that <font color="blue">compete directly with</font> our <font color="blue">Zicam     </font>and  <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> may successfully</font> develop and market     superior or <font color="blue">less expensive products which could</font> render our Zicam and other     <font color="blue">future products less</font> valuable or unmarketable</td>
    </tr>
    <tr>
      <td>Our  business  is  subject to seasonality that may cause our quarterly     operating results to <font color="blue">fluctuate <font color="blue">materially</font></font> and cause the <font color="blue">market price</font> of our     stock to decline          Sales of our existing Zicam products are seasonal in nature and are     <font color="blue">dependent upon</font> the severity of the cough and <font color="blue">cold season</font>, and sales at     <font color="blue">retail generally increase as</font> the level of <font color="blue">population suffering from colds</font>     rises</td>
    </tr>
    <tr>
      <td>During the third quarter <font color="blue">the Company </font>usually realizes <font color="blue">increased sales</font>     <font color="blue">volume as retailers stock</font> our products and order displays to prepare for the     <font color="blue">upcoming cough</font> and <font color="blue">cold season</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>sales (re-orders) to retailers     are highly <font color="blue">dependent upon</font> the incidence of <font color="blue">illness within</font> the population</td>
    </tr>
    <tr>
      <td>Retail <font color="blue">consumption</font> of our products is <font color="blue">highest during</font> the cough and cold     season, which usually runs from October through March</td>
    </tr>
    <tr>
      <td>If there is a mild     cold/flu season, however, revenues from sales of our Zicam <font color="blue">products will</font> be     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Because it is <font color="blue">difficult</font> to anticipate the length and     severity of the cold/flu season, we cannot estimate the <font color="blue">fluctuation</font> of our     <font color="blue">sales from quarter</font> to quarter in a <font color="blue">fiscal year</font> or the impact of the cold/flu     season  year  to  year</td>
    </tr>
    <tr>
      <td>If our operating results fall below financial     analysts’ or investors’ expectations due to cold/flu seasonality factors,     the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> may decline</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may continue</font> to <font color="blue">incur <font color="blue">significant</font> costs</font> resulting <font color="blue">from <font color="blue">product <font color="blue">liability</font></font></font>     claims or <font color="blue">securities <font color="blue">litigation</font></font>          We are subject to <font color="blue"><font color="blue">significant</font> <font color="blue">liability</font> should use</font> or <font color="blue">consumption</font> of     our products cause injury, illness or death</td>
    </tr>
    <tr>
      <td>From late 2003 through <font color="blue">December     </font>2005, numerous lawsuits were <font color="blue">filed against us</font> alleging that our Zicam Cold     Remedy product caused the <font color="blue">permanent loss</font> or <font color="blue">diminishment</font> of the sense of     smell and taste (two of which have <font color="blue">been filed as</font> class <font color="blue">action lawsuits</font>,     <font color="blue">although one</font> of the class <font color="blue">action suits</font> has <font color="blue">been dismissed</font>) relating to our     <font color="blue">Zicam Cold Remedy </font>product</td>
    </tr>
    <tr>
      <td>9       _________________________________________________________________    [61]Table of Contents       Various <font color="blue">defendants</font> in the lawsuits, including <font color="blue">manufacturers</font> and retailers,     have <font color="blue">sought indemnification</font> or other <font color="blue">recovery from us</font> for damages related to     the lawsuits</td>
    </tr>
    <tr>
      <td>Although we carry <font color="blue">product <font color="blue">liability</font></font> insurance, there is no     assurance  that  our  <font color="blue">insurance will</font> be adequate to <font color="blue">cover <font color="blue">liability</font></font> in     <font color="blue">connection with</font> these <font color="blue">product <font color="blue">liability</font></font> lawsuits, or that <font color="blue">product <font color="blue">liability</font></font>     <font color="blue">insurance will</font> continue to be available to us at an <font color="blue">economically reasonable</font>     cost</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims, such as those described in this Form 10-K     for  our  2005 <font color="blue">fiscal year</font>, even if <font color="blue">without merit</font> or for which we have     substantial coverage, could result in <font color="blue"><font color="blue">significant</font> legal defense costs</font>,     <font color="blue">thereby increasing</font> our expenses and lowering our earnings</td>
    </tr>
    <tr>
      <td>Such claims,     whether or not proven to be valid, could have a material adverse effect on     our <font color="blue">product branding</font> and goodwill, resulting in <font color="blue">reduced market acceptance</font> of     our products</td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">adverse decision</font> in <font color="blue">such <font color="blue">litigation</font> could</font>     require <font color="blue"><font color="blue">significant</font> damages</font> to be paid or result in <font color="blue">adverse publicity</font>,     either of <font color="blue">which could <font color="blue">materially</font> <font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font>     and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Separately, <font color="blue">the Company </font>and three of its officers     are also subject to two class <font color="blue">action lawsuits</font> (which have been <font color="blue">consolidated</font>)     alleging  violations  of securities laws</td>
    </tr>
    <tr>
      <td>Any <font color="blue">adverse decision</font> in such     <font color="blue"><font color="blue">litigation</font> could <font color="blue">materially</font> <font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font> and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Because a <font color="blue">significant</font> portion of our business depends <font color="blue">substantially</font> on a     small group of large <font color="blue">national retailers</font>, our sales, operating margins and     income would be <font color="blue"><font color="blue">adversely</font> affected</font> by any <font color="blue">disruption</font> of our <font color="blue">relationship</font>     with  these  retailers,  or  any other material adverse change in such     retailers’ businesses</td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font> a small group of large <font color="blue">national retailers</font>     for our product distribution, such that our top 15 customers accounted for     more than 80prca of our net sales in 2005</td>
    </tr>
    <tr>
      <td>Particularly, Wal-Mart, Walgreens     and CVS <font color="blue">together accounted</font> for more than 40prca of our net sales in 2005</td>
    </tr>
    <tr>
      <td>Should any of our <font color="blue">top customers</font> encounter financial <font color="blue">difficult</font>ies, or stop     carrying our products for any reason, or should our current <font color="blue">relationship</font>     with any of our <font color="blue"><font color="blue">top customers</font> <font color="blue">adversely</font></font> change in any way, the resulting     loss  of  business, exposure on uncollectible receivables and unusable     <font color="blue">inventory could</font> have a material <font color="blue">adverse impact on</font> our <font color="blue">financial position</font> and     results  of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, our results could be <font color="blue">affected by</font>     <font color="blue">fluctuation</font>s in <font color="blue">buying patterns</font> and <font color="blue">inventory levels</font> of these <font color="blue">top customers</font></td>
    </tr>
    <tr>
      <td>We believe that growth in the over-the-counter healthcare products market is     driven, in part, <font color="blue">by factors beyond</font> our control, such as media attention and     <font color="blue">adverse publicity</font></td>
    </tr>
    <tr>
      <td>In  the  event  of future unfavorable scientific results or media     attention, sales of our products could be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>In     addition, if issues arise <font color="blue">concerning</font> the efficacy or safety of any of our     products, or if any of our products receive additional <font color="blue">adverse publicity</font>,     our operating results and <font color="blue">prospects could</font> be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">future growth will depend</font> in part upon our ability to develop and     achieve sales of our <font color="blue">new products</font>, including our new brand, <font color="blue">Nasal Comfort </font>         Although we believe that each of our <font color="blue">products offers unique benefits</font> to     consumers, we cannot be certain that any of the <font color="blue">products will</font> achieve or     continue to <font color="blue">enjoy widespread acceptance by</font> the market</td>
    </tr>
    <tr>
      <td>While we are working     to  increase the <font color="blue">market presence</font> of all of our products, including new     products, we cannot be certain that demand for our <font color="blue">products will</font> grow</td>
    </tr>
    <tr>
      <td>If     <font color="blue">products under</font> the new brand do not achieve <font color="blue">consumer acceptance</font>, operating     results could be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our new business focus means we have a limited operating <font color="blue">history on which</font> to     assess our current and <font color="blue">prospective performance</font>          <font color="blue">Although  </font>we  have  been in <font color="blue">operations</font> for a number of years, the     <font color="blue">significant</font> change of direction and focus in our business that we made in     2001 by exiting the <font color="blue">chewing gum</font> business and <font color="blue">refocusing entirely on</font> the     <font color="blue">development</font>, production and sale of over-the-counter <font color="blue">pharmaceutical</font> products     presents a limited operating <font color="blue">history upon which</font> you <font color="blue">may evaluate</font> our current     and <font color="blue">prospective performance</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">possibility</font> of our <font color="blue">future success must</font> be     considered relative to the problems, challenges, complications and delays     <font color="blue">frequently encountered</font> in <font color="blue">connection with</font> the <font color="blue">development</font> and operation of a     new business, and the <font color="blue">development</font> and marketing of <font color="blue">relatively <font color="blue">new products</font></font>     such as the Zicam products</td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________    [62]Table of Contents       Unanticipated   problems   associated  with  product  <font color="blue">development</font>  and     <font color="blue">commercialization</font> could <font color="blue">adversely</font> affect our operating results               Our successful <font color="blue">development</font> of existing and <font color="blue">new products</font> is subject     to  the  risks  of  failure  and <font color="blue">delay inherent</font> in the <font color="blue">development</font> and     <font color="blue">commercialization</font> of <font color="blue">products based on innovative technologies</font></td>
    </tr>
    <tr>
      <td>These risks     include the <font color="blue">possibilities</font> that:       •   we may experience <font color="blue">unanticipated</font> or <font color="blue">otherwise negative research</font> and     <font color="blue">development</font> results;          •   existing or <font color="blue">proposed products</font> may be found to be <font color="blue">ineffective</font> or     unsafe, or <font color="blue">may otherwise fail</font> to receive required <font color="blue"><font color="blue">regulatory</font> clearances</font> or     approvals;         •   we may find that existing or <font color="blue">proposed products</font>, while effective, are     uneconomical to <font color="blue">commercialize</font> or market;         •   we may be unable to produce <font color="blue">sufficient product inventories</font> to meet     <font color="blue">customer demand</font>;         •   existing or <font color="blue">proposed products</font> do not achieve <font color="blue">broad market acceptance</font>;         •   existing or <font color="blue">proposed products</font> do not <font color="blue">attain broad distribution</font> or     <font color="blue">retail shelf space</font>; or         •   <font color="blue"><font color="blue">proprietary</font> rights</font> held <font color="blue">by <font color="blue">third parties</font> preclude us from</font> developing     or <font color="blue">marketing existing</font> or <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to develop and <font color="blue">commercialize</font> our <font color="blue">existing products</font>     or any <font color="blue">new products</font>, including our <font color="blue">Nasal Comfort </font>product, on a <font color="blue">timely basis</font>     and within our <font color="blue">financial budgets could</font> have a material adverse effect on our     operating results and <font color="blue">future prospects</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">provide scientific proof</font> for product claims may <font color="blue">adversely</font>     affect our sales               The marketing of our Zicam products involves claims that these     <font color="blue">products assist</font> in reducing the duration and severity of the <font color="blue">common cold</font> (in     the case of <font color="blue">Zicam Cold Remedy </font>products) and <font color="blue">controlling allergy symptoms</font> (in     the case of <font color="blue">Zicam Allergy Relief</font>)</td>
    </tr>
    <tr>
      <td><font color="blue">Under FDA and FTC </font>rules, we are required     to obtain <font color="blue">scientific data</font> to support any health claims we make <font color="blue">concerning</font>     our products</td>
    </tr>
    <tr>
      <td>We have obtained <font color="blue">scientific data</font> for our product claims;     however, we cannot be certain that the <font color="blue">scientific data</font> we have obtained in     support of our claims will be deemed acceptable to the FDA, FTC or other     <font color="blue"><font color="blue">regulatory</font> bodies</font></td>
    </tr>
    <tr>
      <td>If any <font color="blue">regulatory</font> body requests supporting information     and we are unable to provide support that is acceptable, either the FDA or     FTC <font color="blue">could force us</font> to stop making the claims in question or <font color="blue">restrict us from</font>     selling the <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>FDA and other <font color="blue">government regulation may restrict</font> our ability to sell our     products               We  are subject to <font color="blue">various federal</font>, state and <font color="blue">local laws</font> and     <font color="blue">regulations</font>  <font color="blue">affecting</font> our business</td>
    </tr>
    <tr>
      <td>Our Zicam products are subject to     <font color="blue">regulation by</font> the FDA, including <font color="blue">regulations</font> with respect to labeling of     products, approval of <font color="blue">ingredients</font> in products, claims made regarding the     products, and <font color="blue">disclosure</font> of product <font color="blue">ingredients</font></td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">comply with</font>     these <font color="blue">regulations</font> or if these <font color="blue">regulations</font> change in the future, the FDA     <font color="blue">could force us</font> to stop selling the <font color="blue">affected products</font> or require us to incur     substantial costs in <font color="blue">adopting measures</font> to maintain <font color="blue">compliance with</font> these     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>came to believe that any of our products caused harm     to consumers, we could be required to stop selling that product or subject     the product to a recall</td>
    </tr>
    <tr>
      <td>Our <font color="blue">advertising</font> claims regarding our products are     subject to the <font color="blue">jurisdiction</font> of the FTC as well as the FDA In both cases we     are  required  to obtain <font color="blue">scientific data</font> to support any <font color="blue">advertising</font> or     labeling  health  claims  we make <font color="blue">concerning</font> our products, although no     pre-clearance or filing is required to be made <font color="blue">with either agency</font></td>
    </tr>
    <tr>
      <td>If we are     unable to provide the required support for such claims, the FTC <font color="blue">may stop us</font>     from making such claims or require us to stop selling the <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>On March 10, 2005, the National Advertising Division (NAD) of the Council of     Better Business Bureaus, an <font color="blue">investigative</font> arm of the <font color="blue">advertising</font> industry’s     voluntary self-regulation program, issued a <font color="blue">press release</font> announcing the     results of a review of Matrixx’s <font color="blue">advertising</font> claims</td>
    </tr>
    <tr>
      <td>The NAD determined,     among other things, that Matrixx’s claims that its product, Zicam® Cold     Remedy Nasal Gel, resolves colds 3X faster when taken at the <font color="blue">first sign</font> of a     cold, that using the product results in a <font color="blue">less severe cold</font>, and the promise     that these benefits are <font color="blue">clinically proven</font>, were <font color="blue">substantiated by competent</font>     and <font color="blue">reliable scientific evidence</font></td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________    [63]Table of Contents       If we are unable to protect our intellectual property or if we infringe the     intellectual  property  of  others, our <font color="blue">financial condition</font> and future     <font color="blue">prospects could</font> be <font color="blue">materially</font> harmed               We rely <font color="blue">significant</font>ly on the <font color="blue">protections afforded by patent</font> and     <font color="blue">trademark registrations</font> that we <font color="blue">routinely seek from</font> the US Patent and     Trademark Office (“USPTO”) and from similar agencies in foreign countries</td>
    </tr>
    <tr>
      <td>We cannot be certain that any patent or <font color="blue">trademark application</font> that we file     will be <font color="blue">approved by</font> the USPTO or other <font color="blue">foreign agencies</font></td>
    </tr>
    <tr>
      <td>In addition, we     cannot be certain that we will be able to <font color="blue">successfully defend</font> any trademark,     trade  name  or  patent  that  we hold against claims from, or use by,     <font color="blue">competitors</font> or other <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>No <font color="blue">consistent policy</font> has <font color="blue">emerged from</font>     the USPTO or the courts regarding the breadth of claims allowed or the     degree of <font color="blue">protection afforded under bio<font color="blue">technology</font></font> and similar patents</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">future success will depend on</font> our ability to <font color="blue">prevent others from infringing</font>     on  our  <font color="blue"><font color="blue">proprietary</font> rights</font>, as well as our ability to operate without     <font color="blue">infringing upon</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>We may be required at     times to take <font color="blue">legal action</font> to protect our <font color="blue"><font color="blue">proprietary</font> rights</font> and, despite     our <font color="blue">best efforts</font>, we may be sued for <font color="blue">infringing on</font> the <font color="blue">patent rights</font> of     others</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> is costly and, even if we prevail, the cost of     <font color="blue">such <font color="blue">litigation</font> could</font> <font color="blue">adversely</font> affect our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If we do not     prevail,  in addition to any damages we might have to pay, we could be     required to stop the <font color="blue">infringing activity</font> or obtain a license</td>
    </tr>
    <tr>
      <td>We cannot be     certain that any required <font color="blue">license would</font> be available to us on acceptable     terms, or at all</td>
    </tr>
    <tr>
      <td>If we fail to obtain a license, our business might be     <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">seeking patent protection</font>, we     rely upon a <font color="blue">combination</font> of non-<font color="blue">disclosure</font> agreements, other <font color="blue">contractual</font>     <font color="blue">restrictions</font> and <font color="blue">trade secrecy laws</font> to <font color="blue">protect <font color="blue">proprietary</font></font> information</td>
    </tr>
    <tr>
      <td>There can be no assurance that these steps will be adequate to prevent     <font color="blue">misappropriation</font> of our <font color="blue">proprietary</font> information or that our <font color="blue">competitors</font> will     not <font color="blue">independently</font> develop <font color="blue">technology</font> or <font color="blue">trade secrets</font> that <font color="blue">compete with</font> our     <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>We do not have <font color="blue">manufacturing</font> <font color="blue">capabilities</font> of our own               We  currently do not have the physical or <font color="blue">human resources</font> to     <font color="blue">independently</font> manufacture our Zicam products or any other products that we     may develop</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently outsource</font> all of our <font color="blue">product <font color="blue">manufacturing</font></font> and     packaging  <font color="blue">operations</font>  and intend to continue this outsourcing for the     foreseeable  future</td>
    </tr>
    <tr>
      <td>If we are unable to enter into cost-effective or     otherwise suitable arrangements for <font color="blue">manufacturing</font> our Zicam products or any     other products, or if our third-party contractors fail to <font color="blue">adequately</font> perform     their <font color="blue">manufacturing</font> <font color="blue">operations</font>, our sales and related financial results     could be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>If, in the future, we decide to     establish our own <font color="blue">manufacturing</font> facilities, we will require substantial     <font color="blue">additional funds</font> and <font color="blue">significant</font> additional personnel to undertake such     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that such funding or a sufficient number of     <font color="blue">such qualified persons will</font> be available for such an undertaking</td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">product backlogs</font>               We have <font color="blue">established inventory</font> plans to <font color="blue">support sales expectations</font>     for all of our products</td>
    </tr>
    <tr>
      <td>However, we cannot be certain that these measures     will be sufficient to <font color="blue">prevent backlogs</font> of products in the future</td>
    </tr>
    <tr>
      <td>Any such     <font color="blue">future backlogs will potentially</font> result in higher production costs, higher     <font color="blue">freight costs</font> to <font color="blue">expedite shipment</font> of <font color="blue">raw materials</font> and finished goods,     fines from certain retailers, cancelled orders and <font color="blue">lost revenue</font></td>
    </tr>
    <tr>
      <td>These in     turn  could  <font color="blue">materially</font> affect our results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>Loss of <font color="blue">key personnel</font>               We have a limited number of employees and our <font color="blue">success depends on</font>     the <font color="blue">continued services</font> of our <font color="blue">senior <font color="blue">management</font></font> and <font color="blue">key employees as well as</font>     our  ability to <font color="blue">attract additional members</font> to our <font color="blue"><font color="blue">management</font> team with</font>     experience in the <font color="blue">consumer health products industry</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">unexpected loss</font> of     the  services  of any of our <font color="blue">management</font> or other <font color="blue">key personnel</font>, or our     <font color="blue">inability</font> to attract new <font color="blue">management</font> when necessary, could have a material     adverse effect upon our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>To <font color="blue"><font color="blue">protect against</font> various potential liabilities</font>, we maintain a variety of     <font color="blue">insurance programs</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>increases in the cost or <font color="blue">decreases</font> in the     <font color="blue">availability</font>  of  such  insurance could <font color="blue">adversely</font> impact our financial     condition</td>
    </tr>
    <tr>
      <td>We maintain insurance, including property, general and product     <font color="blue">liability</font>,  and <font color="blue">directors</font>’ and officers’ <font color="blue">liability</font>, to <font color="blue">protect against</font>     <font color="blue">potential loss exposures</font></td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">risks <font color="blue">associated with</font> product</font>     <font color="blue">liability</font> insurance discussed above, we <font color="blue">cannot predict whether deductible</font> or     retention  amounts  <font color="blue">associated with</font> all of our <font color="blue">insurance programs</font> will     increase, or whether <font color="blue">insurance coverage</font>, generally speaking, will be reduced     in the future</td>
    </tr>
    <tr>
      <td>To the extent that losses occur, there could be an adverse     affect on our financial results depending on the nature of the loss and the     level of <font color="blue">insurance coverage</font> we have maintained</td>
    </tr>
    <tr>
      <td>From time to time, we may     reevaluate and change the types and levels of <font color="blue">insurance coverage</font> that we     purchase</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________    [64]Table of Contents       Our board of <font color="blue">directors</font> is authorized to <font color="blue">issue shares</font> of <font color="blue">preferred stock</font> that     could have rights superior to our <font color="blue">outstanding shares</font> of <font color="blue">common stock</font>, and,     if issued, could <font color="blue">adversely</font> impact the value of our <font color="blue">common stock</font>               Our <font color="blue">certificate</font> of <font color="blue">incorporation permits</font> our board of <font color="blue">directors</font>,     in its <font color="blue">sole discretion</font>, to issue up to 2cmam000cmam000 shares of <font color="blue">authorized but</font>     unissued <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">shares may</font> be issued by our board without     <font color="blue">further action by</font> our <font color="blue">shareholders</font>, and may include any of the following     rights  (among others) as our <font color="blue">board may</font> determine, <font color="blue">which rights may</font> be     superior to the rights of our outstanding <font color="blue">common stock</font>:       •   <font color="blue">voting rights</font>, including the right to vote as a class <font color="blue">on particular</font>     matters;         •   <font color="blue">preferences as</font> to dividends and <font color="blue">liquidation rights</font>;         •   <font color="blue">conversion rights</font>;         •   anti-dilution protections; and         •   <font color="blue">redemption rights</font>               Since our board of <font color="blue">directors</font> has the authority to determine, from     time to time, the terms of our authorized <font color="blue">preferred stock</font>, there is no limit     on the amount of <font color="blue">common stock</font> that could be <font color="blue">issuable upon conversion</font> of any     <font color="blue">future series</font> of <font color="blue">preferred stock</font> that may be issued</td>
    </tr>
    <tr>
      <td>The rights of holders     of our <font color="blue">common stock</font> will be subject to, and may be <font color="blue"><font color="blue">adversely</font> affected</font> by,     the rights of the holders of any series of <font color="blue">preferred stock</font> that may be     issued in the future</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">market price</font> of our <font color="blue">common stock</font> may     be <font color="blue"><font color="blue">adversely</font> affected</font> by the issuance of any series of <font color="blue">preferred stock</font> with     voting or other rights superior to those of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The issuance     of any series of <font color="blue">preferred stock</font> could also have the effect of making it     more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our outstanding     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The price of our stock <font color="blue">may continue</font> to be volatile               The <font color="blue">market price</font> of our <font color="blue">common stock</font>, which is quoted for trading     on the Nasdaq National Market, has <font color="blue">been highly volatile</font> and <font color="blue">may continue</font> to     be volatile in the future</td>
    </tr>
    <tr>
      <td>Any or a <font color="blue">combination</font> of the <font color="blue">following factors</font>     could  cause  the market value of our <font color="blue">common stock</font> to <font color="blue">decline quickly</font>:     operating results that differ from market expectations, negative or other     <font color="blue">unanticipated</font> results of <font color="blue">clinical trials</font> or other testing, delays in product     <font color="blue">development</font>, technological innovations or <font color="blue">commercial product introductions</font>     by  our  <font color="blue">competitors</font>,  changes in government <font color="blue">regulations</font>, <font color="blue">development</font>s     <font color="blue">concerning</font>  <font color="blue"><font color="blue">proprietary</font> rights</font>, including pending or <font color="blue">threatened patent</font>     <font color="blue">litigation</font>, public concerns regarding the safety of any of our products, the     outcome of <font color="blue">litigation</font> against the Company, and general economic and stock     market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market</font> has experienced, and it <font color="blue">may continue</font> to     experience, <font color="blue">significant</font> price and volume <font color="blue">fluctuation</font>s</td>
    </tr>
    <tr>
      <td>Historically, these     <font color="blue">fluctuation</font>s particularly affect the <font color="blue">market price</font>s of <font color="blue">equity securities</font> of     small <font color="blue">capitalization companies</font>, like Matrixx</td>
    </tr>
    <tr>
      <td>Often, the effect on the price     of such securities is <font color="blue">disproportionate</font> to the operating performance of such     companies</td>
    </tr>
    <tr>
      <td>In our case, such     <font color="blue">fluctuation</font>s may <font color="blue">adversely</font> affect our stockholders’ ability to dispose of     their shares of Matrixx at a price equal to or above the <font color="blue">price at which</font> they     <font color="blue">purchased such shares</font></td>
    </tr>
  </tbody>
</table>